Investment House LLC cut its stake in shares of Charles River Laboratories International Inc. (NYSE:CRL) by 0.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 88,910 shares of the company’s stock after selling 305 shares during the period. Charles River Laboratories International makes up 1.2% of Investment House LLC’s holdings, making the stock its 25th largest position. Investment House LLC owned approximately 0.19% of Charles River Laboratories International worth $7,330,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of CRL. State Street Corp boosted its stake in Charles River Laboratories International by 3.0% in the first quarter. State Street Corp now owns 1,289,582 shares of the company’s stock valued at $97,928,000 after buying an additional 37,420 shares during the period. Canada Pension Plan Investment Board boosted its stake in Charles River Laboratories International by 4.1% in the first quarter. Canada Pension Plan Investment Board now owns 5,100 shares of the company’s stock valued at $387,000 after buying an additional 200 shares during the period. Acrospire Investment Management LLC purchased a new stake in Charles River Laboratories International during the first quarter valued at $327,000. JPMorgan Chase & Co. boosted its stake in Charles River Laboratories International by 206.5% in the first quarter. JPMorgan Chase & Co. now owns 156,443 shares of the company’s stock valued at $11,880,000 after buying an additional 105,399 shares during the period. Finally, Massmutual Trust Co. FSB ADV boosted its stake in Charles River Laboratories International by 4.4% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,769 shares of the company’s stock valued at $210,000 after buying an additional 117 shares during the period. 96.69% of the stock is owned by institutional investors and hedge funds.

Shares of Charles River Laboratories International Inc. (NYSE:CRL) traded up 0.05% during midday trading on Tuesday, hitting $80.51. 280,691 shares of the stock were exchanged. Charles River Laboratories International Inc. has a 12-month low of $59.99 and a 12-month high of $89.18. The firm has a 50 day moving average of $82.86 and a 200 day moving average of $81.93. The firm has a market cap of $3.81 billion, a P/E ratio of 27.20 and a beta of 1.21.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.10. The business earned $434.10 million during the quarter, compared to analyst estimates of $425.05 million. Charles River Laboratories International had a net margin of 9.49% and a return on equity of 25.18%. The company’s revenue was up 27.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.96 earnings per share. Equities analysts forecast that Charles River Laboratories International Inc. will post $4.45 EPS for the current fiscal year.

A number of equities analysts recently weighed in on CRL shares. Evercore ISI reaffirmed a “hold” rating and set a $91.50 price objective (up previously from $83.50) on shares of Charles River Laboratories International in a research report on Thursday, August 4th. Credit Suisse Group AG started coverage on shares of Charles River Laboratories International in a research report on Monday, June 20th. They set a “neutral” rating and a $84.00 price objective for the company. Zacks Investment Research cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, July 22nd. Jefferies Group increased their price objective on shares of Charles River Laboratories International from $94.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, August 4th. Finally, Citigroup Inc. increased their price objective on shares of Charles River Laboratories International from $85.00 to $90.00 and gave the stock a “neutral” rating in a research report on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $86.21.

In related news, insider Davide Molho sold 7,877 shares of the company’s stock in a transaction that occurred on Tuesday, August 30th. The shares were sold at an average price of $84.10, for a total transaction of $662,455.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director George Massaro sold 3,740 shares of the company’s stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $83.09, for a total transaction of $310,756.60. Following the transaction, the director now directly owns 18,935 shares of the company’s stock, valued at approximately $1,573,309.15. The disclosure for this sale can be found here. Corporate insiders own 2.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

5 Day Chart for NYSE:CRL

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International Inc. (NYSE:CRL).

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.